ResourceClinical Diagnostics
TruSight Oncology Comprehensive (EU): A new era for better patient outcomes
19 Mar 2026In this brochure, Illumina highlights TruSight™ Oncology Comprehensive (EU), a next-generation sequencing solution that enables institutions to offer in-house comprehensive genomic profiling for cancer, emphasizing its clinically relevant biomarker coverage, alignment with drug labels and European Society for Medical Oncology (ESMO) recommendations. By implementing the test in-house, labs gain control over sample logistics and data management, improve sample QC and biomarker-informed case rates, and strengthen their role as precision medicine providers.
Related products
Request Quote for All Products
TruSight™ Oncology Comprehensive
IlluminaThe first CE-marked IVD kitted solution for comprehensive genomic profiling (CGP) of DNA and RNA variants, plus MSI and TMB, for multiple solid tumor types.
Links
Tags
Next Generation SequencingNext-generation sequencing (NGS), also known as whole-genome sequencing, high-throughput sequencing and massive parallel sequencing, produces and analyses thousands to millions of nucleotide sequences at once. Sequencing systems operate via varying technologies depending on the manufacturer, including sequencing by synthesis, ligation, pyrosequencing, ion semiconductor and single-molecule real-time sequencing. For NGS, library preparation is paramount to successful sequencing. In this section, explore a range of library preparation kits, from targeted, amplicon-based or hybridization-based kits including epigenomic, transcriptomic and genomic workflows to fragmentation kits. Find the best next-generation sequencing products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.